Refine by
Covid 19 Diagnostic Testing Articles & Analysis
101 news found
In the past year miDiagnostics has been working on the development of an ultra-fast PCR test based on imec technology, to detect COVID-19, with a test result in less than 15 minutes. In cooperation with Brussels Airport, this nasal-swab ultra-fast PCR test, as well as the new breath sampler developed by imec and licensed by miDiagnostics, will be tested in practice during a study at the ...
“We are committed to continuing to find ways to expand testing innovations and solutions as we continue to fight COVID-19,” said Governor Charlie Baker. ...
Founded in 2020 in response to the COVID-19 pandemic, Virusight, which is an AI software company, was created to develop an accurate, real-time virus diagnosis solution. The company uses unique spectral acquisition and analysis technology, for pathogenic diagnosis. The company is currently in the midst of developing and testing revolutionary COVID-19 rapid tests, based on Newsight ...
And there has been a lot of research that shows they exacerbate the disparities in health outcomes we see in the United States across race or ethnicity, age, socioeconomic status, sexual identity, and geography. The idea of making blood testing more convenient and accessible inspired me to join Babson Diagnostics. ...
The CE Certificate is quality proof that Reetoo’s COVID-19 self-test kit is well-qualified to be applied in the global market. Many countries have encouraged self-administered antigen tests to screen for infection due to the resurgence of COVID-19. Reetoo's product is capable of facing ...
The COVID-19, pandemic amongst other changes in our lifestyle, has introduced us to new medical terms that we are not quite familiar with, such as the term PCR (polymerase chain reaction). ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. ...
Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch of its new B2C e-commerce website, abingdonsimplytest.com. ...
The Virusight solution demonstrated an overall sensitivity of 92.7% (positive percent agreement) and specificity of 96.8% (negative percent agreement) as compared to an EC marked RT-PCR and was shown to be a safe and reliable test for the detection of SARS-CoV-2 antigens and/or virus particles in oral swab samples, providing diagnosis of active ...
Prior to 2020 and the COVID-19 pandemic, the market for disposable medical supplies in Panama steadily grew at an average rate of 10% over the last decade, due to the growing population and increased public and private investment in the health sector. As a result of the pandemic, Panama has significantly increased spending on disposable medical supplies and is prepared to continue devoting ...
The Test is now available for use across Europe and other countries that accept CE-IVD marking, providing a powerful pandemic and endemic management tool in industries where fast and reliable decentralized testing is crucial. With the launch of its first product, miDiagnostics enters the commercial phase, marking an important milestone in the company’s development. Ultra-fast and reliable ...
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2022 and the outlook for the full year 2022. ...
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety. All efficacy ...
Anavasi Diagnostics announced today that it has submitted the required EUA Clinical Study Data for the AscencioDx®, the molecular diagnostic platform for the detection of RNA indicative of the presence of the SARS-CoV-2/COVID-19 virus, to the Food and Drug Administration (FDA). ...
This year we aim to launch our first ultra-rapid COVID-19 test products, followed by additional in-vitro diagnostic panels, including inflammation, triage, and hormone tests; as we begin to realize our vision of decentralizing diagnostic ...
Thanks to the support from the Health Innovation Hub Ireland, HiberGene were able to work with Bon Secours Health System Ireland, Cork in carrying out a very successful clinical evaluation of its PCR Adapt Covid-19 test, with excellent results. Clinical Need The Gold Standard diagnostic for ...
This financing will enable Visby Medical to scale production capacity from tens to hundreds of thousands of tests per month, further expand the product menu to include COVID + influenza A/B combination testing, antimicrobial resistance panels, and deliver the power of PCR diagnostics to consumers at-home. ...
Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing. The DETECTR BOOST platform is a turnkey, CRISPR-based molecular diagnostic system that enables ...
MeMed, a leader in host response technologies, today announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. ...
ByMeMed